US banking crisis opens the door for this stock

Dear Reader,  Time is ticking for the US.  Debt ceiling negotiations have been tense and no decision has been made.  The Treasury Department says the US could default as early as June 1, meaning they’re running out of time to make a deal.  Add that to the US banking crisis and it’s a double hit to the economy.  But, this ticking time bomb could create an unlikely winner as the market recalibrates.  We’re talking about small-cap biotech stocks.  Right now, Apple is worth more than the combined value of the 2,000 small-cap companies in the Russell 2000 index. $100 billion more to be exact.  Why?  Because the Russell 2000 has a ton of regional bank stocks that crashed and burned in recent months.  Luckily, the index is rebalancing its holdings and according to Goldman Sachs, it has its eye on biotech stocks.  Which is why we can’t stop talking about [Mainz Biomed (NASDAQ:MYNZ)](.  This company has continued to climb since we began coverage on May 2 and is now hovering just under the $5 mark. If you had gotten in then, you would already be up over 25%!  With its main early cancer detection product already approved and marketed in the EU, it's only a matter of time before the FDA gives the green light for availability in the US.  It’s no surprise that top analysts from HC Wainwright, JonesTrading, and Cantor Fitzgerald are giving this company a [buy or overweight rating](.  It’s pretty clear that this company is poised for success.  This is definitely a story you don’t want to miss out on.  [Do your research and click here to learn more about this red hot stock now.](        Disclaimer: Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities. --------------------------------------------------------------- This message is a PAID ADVERTISEMENT for Mainz Biomed (NASDAQ:MYNZ) from Market Jar Media, Inc. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $3000. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Mainz Biomed (NASDAQ:MYNZ) or Market Jar Media, Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Mainz Biomed (NASDAQ:MYNZ) on StreetSignals website for additional information about the relationship between Market Jar Media, Inc and Mainz Biomed (NASDAQ:MYNZ). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click [Unsubscribe](. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com